An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing

A Phase 1 Study of AGENT-797 to treat moderate to severe acute respiratory syndrome in COVID-19 patients.

This is a Phase 1 study to evaluate the safety and efficacy of agenT-797, an unmodified, allogeneic iNKT therapy, in patients with coronavirus disease 2019 (COVID-19), requiring mechanical ventilation, and with moderate to severe ARDS as determined by the Berlin definition.

Learn More (clinicaltrials.gov)

Currently No Enrollment.